Aclarubicin in advanced thyroid cancer: a phase II study.
Twenty-four patients with metastatic thyroid cancer were treated with aclarubicin intravenously at a dose of 25-30 mg/m2 daily for 4 days and treatment was repeated every 3 weeks. None of the patients had previously received chemotherapy. Twenty-three patients received two or more treatment cycles and were evaluated for their response. One complete remission and four partial remissions were noted (objective remission rate 22%). Mean survival time was 57 weeks. Side-effects were evaluated in 24 patients with 18 patients receiving prophylactic antiemetic therapy. Nausea was observed in 18 (75%) and vomiting occurred in three patients (13%). In 15 patients (63%) there was mild myelosuppression. We conclude that aclarubicin alone represents an effective therapy in patients with metastatic thyroid cancer and that side-effects are minor.
Samonigg
H
H
Department of Internal Medicine, Karl-Franzens-University at Graz, Austria.
Hossfeld
D K
DK
Spehn
J
J
Fill
H
H
Leb
G
G
D015250:Aclarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013964:Thyroid Neoplasms / Q000188:drug therapy*
D015250:Aclarubicin